Pfizer Edges Higher As Covid Sales Decline, But Still Beat ExpectationsInvestors Business Daily • 02/04/25
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay offCNBC • 02/04/25
Pfizer Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate AnalystsBenzinga • 02/04/25
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER TrialBusiness Wire • 02/03/25
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 01/30/25
Dividends And Dynamite: 10 High-Yield Blue-Chip Bargains You Don't Want To MissSeeking Alpha • 01/30/25
PFE Stock Rises on Reports of Averting Proxy Fight With Activist InvestorZacks Investment Research • 01/28/25
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers SymposiumBusiness Wire • 01/28/25
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer PatientsBenzinga • 01/27/25
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For NowInvestors Business Daily • 01/27/25